Current cancer immunotherapies such as ICI therapy focus mostly on the MHC-restricted αβ T cells, while γδ T cells also present potent anti-tumor activity independently from MHC restriction, and thus immunotherapy based on Vγ9Vδ2 T cells, the predominant subtypes of γδ T cells, enable favorable clinical outcomes in various cancers with low toxicity [169, 170]. Here, HLA-C is linked to neoplasm.